
Opinion|Videos|January 10, 2025
Sequencing Consequences for Earlier Line Use of Bispecifics in B-Cell Lymphomas
Panelists discuss how the sequencing of bispecific therapies in first-line vs later-line settings should be guided by factors such as disease stage, prior treatments, and patient-specific characteristics to optimize therapeutic outcomes.
Advertisement
Episodes in this series

Video content above is prompted by the following:
What considerations should guide the sequencing of bispecific therapies in first-line vs later-line settings?
Advertisement
Related to this article

SaTScan detects an acute HCV outbreak cluster in California, showing the potential of automated surveillance, though real-time testing is needed.

The editor in chief of Evidence-Based Oncology, who was recently named medical director of Precision Medicine for The US Oncology Network, discussed milestones met and those still to be achieved.

Genetic analysis finds 125 loci shared by insomnia and CRP, with Mendelian randomization favoring an effect from insomnia liability to inflammation.

Cleveland roundtable panelists across 4 disease states name access, not evidence, as the shared barrier to care.

Alice Hall-Partyka, JD, a partner at Crowell & Moring explains the lawsuits challenging CMS' Medicaid rule on pediatric gender care and its legal weak points.

Siva Mohan, MD, explains how drug costs drive silent nonadherence, PA burden, and biosimilar hesitancy, and what payers can do about it.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About the One Big Beautiful Bill Act
2
PBM Reform and Supportive Care Needs: Nicolas Ferreyros
3
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
4
Genetic Analysis Links Insomnia Liability to Higher Inflammation Marker
5


